Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: Assessment using data simulation

Pharmacogenetics and Genomics

Volumn 25, Issue 10, 2015, Pages 491-500

  Syn, Nicholas L X ^a,d   Lee, Soo Chin ^a,d   Brunham, Liam R ^b,d   Goh, Boon Cher ^a,c,d  

^a National University Cancer Institute   (Singapore)

^b Department of Medicine ^*  (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

anticoagulation; clinical trial simulation; CYP2C9; personalized medicine; pharmacoethnicity; pharmacogenetics; pharmacokinetic pharmacodynamic; systems biology; VKORC1; warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONCENTRATION AT STEADY-STATE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG RESEARCH; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HEREDITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; PHARMACOGENETICS; PRIORITY JOURNAL; SIMULATION; VOLUME OF DISTRIBUTION; ALGORITHM; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT ANALYSIS; COMPUTER SIMULATION; DEMOGRAPHY; DOSE RESPONSE; GENETICS; STATISTICS; TIME FACTOR;

AFRICAN AMERICANS; ALGORITHMS; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; COMPUTER SIMULATION; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; STATISTICS AS TOPIC; TIME FACTORS; WARFARIN;

EID: 84941961000     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000165     Document Type: Article

References (30)

1. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5:262-270.
2. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-719.
3. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C98 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2010; 10:1243-1255.
4. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-764.
5. Tham L-S, Goh B-C, Nafziger A, Guo J-Y, Wang L-Z, Soong R, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006; 80:346-355.
6. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84:326-331.
7. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther 2011; 90:701-706.
8. Lenzini P, Wadelius M, Kimmel SE, Anderson JL. Integration of genetic, clinical, and INR data to refine Warfarin dosing. Clin Pharmacol Ther 2010; 87:572-578.
9. British Columbia. Medical Services Commission of British Columbia Guidelines and Protocols Advisory Committee B. Warfarin Therapy Management 2010. Available at: http://www.bcguidelines.ca/. [accessed 4 January 2015].
10. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369:2294-2303.
11. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012; 125:1997-2005.
12. Burmester JK, Berg RL, Yale SH, Rottscheit CM, Glurich IE, Schmelzer JR, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011; 13:509-518.
13. Kimmel SE, French B, Kasner SE, Johnson Ja, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369:2283-2293.
14. Hamberg A-K, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 2010; 87:727-734.
15. Dai D, Xu R, Hu L, Wang S, Geng P, Yang J, et al. CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J 2014; 14:85-92.
16. Lei X, Guo Y, Sun J, Zhou H, Liu Y, Liang P, et al. Accuracy assessment of pharmacogenetic algorithms for warfarin dose prediction in Chinese patients. Am J Hematol 2012; 87:541-544.
17. Hylek EM, Phillips KA, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. JAMA 2001; 285:2370-2375.
18. Tai G, Farin F, Rieder MJ, Dreisbach AW, Veenstra DL, Verlinde CLMJ, et al. In-vitro and in-vivo effects of the CYP2C911 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics 2005; 15:475-481.
19. Dai D, Wang Y, Wang S, Geng P, Hu L, Hu G, et al. In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population. Acta Pharmacol Sin 2013; 34:1449-1456.
20. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MM, et al. Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115:3827-3834.
21. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 1989; 5:303-311. Discussion 312-313.
22. Huisinga W, Solms a, Fronton L, Pilari S. Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT Pharmacometrics Syst Pharmacol 2012; 1:e4.
23. Johnson JA, Gong L, Gage BF, Scott SA, Stein CM, Anderson JL, et al. clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2009; 90:625-629.
24. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, et al. Genetic variants associated with warfarin dose in African-American individuals: A genome-wide association study. Lancet 2013; 382:790-796.
25. Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics 2015; 25:73-81.
26. Chen J, Shao L, Gong L, Luo F, Wang J, Shi Y, et al. A pharmacogeneticsbased warfarin maintenance dosing algorithm from Northern Chinese patients. PLoS One 2014; 9:e105250.
27. Patel MR, Mahaffey KW, Garg J, Breithardt G, Halperin JL, Hankey GJ, et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
28. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom JW. Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
29. Donovan JL, Drake JA, Whittaker P, Tran MT. Pharmacy-managed anticoagulation: Assessment of in-hospital efficacy and evaluation of financial impact and community acceptance. J Thromb Thrombolysis 2006; 22:23-30.
30. Kim I-W, Kim KI, Chang H-J, Yeon B, Bang S-J, Park T, et al. Ethnic variability in the allelic distribution of pharmacogenes between Korean and other populations. Pharmacogenet Genomics 2012; 22:829-836.